Bufalin: a potential drug for regulating EGFR-TKIs resistance in lung cancer via the EGFR-PI3K/Akt-mTOR signaling.

ABSTRACT:

Background

Bufalin has shown potential in overcoming cancer resistance to osimertinib and sorafenib in epidermal growth factor receptor (EGFR)-mutated lung cancer. This study investigated the regulatory effect of bufalin on EGFR tyrosine kinase inhibitors (TKIs) resistance in lung cancer.

Methods

The cell experiments including the MTT assay, flow cytometry, and real-time polymerase chain reaction (RT-PCR) were used to determine the effects of bufalin and/or EGFR-TKIs gefitinib on the growth, proliferation, cycle, apoptosis, and expressions of genes linked to the EGFR-phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)-mammalian target of rapamycin (mTOR) signal pathway of human non-small cell lung cancer cell line H1975. In animal experiments, a model of H1975 cel

SUBMITTER: Bai Y 

PROVIDER: S-EPMC12776075 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature